RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Pharmaceutical Industry

A collection of news and information related to Pharmaceutical Industry published by this site and its partners.

Top Pharmaceutical Industry Articles

Displaying items 23-33
  • Chicago misses out in AbbVie-Calico pharma deal

     Chicago misses out in AbbVie-Calico pharma deal
    A few days ago, Calico, a Google-backed biotech company, announced that it would build a California-based research and development facility to invent new drugs to combat diseases afflicting the elderly. Half of the initial $500 million investment...
  • Hospira talks for $5 billion tax inversion deal stall

    Hospira talks for $5 billion tax inversion deal stall
    Lake Forest-based drugmaker Hospira's talks to buy the medical nutrition unit of Danone and use the deal to move its tax domicile abroad have stalled, according to people familiar with the matter, as attempts by U.S. companies to relocate abroad and cut...
  • AbbVie partners with Google to develop new drugs for aging

    AbbVie partners with Google to develop new drugs for aging
    A startup backed by Google, the Silicon Valley powerhouse whose innovations range from its eponymous search engine to self-driving cars, is teaming up with a North Chicago drug company to develop treatments for diseases tied to aging. Drugmaker AbbVie...
  • Google's Calico, AbbVie forge deal against diseases of aging

    (Reuters) - U.S. drugmaker AbbVie Inc and Calico, a new company set up by Google Inc to cure diseases of aging, will each invest $250 million to help create Calico research facilities and collaborate on discovery and development of new medicines. AbbVie...
  • U.S. seeks to speed up production of Ebola drug

    U.S. seeks to speed up production of Ebola drug
    With the Ebola outbreak threatening to spiral out of control, U.S. officials unveiled a multimillion-dollar plan Tuesday aimed at getting a promising drug out of American research labs and into African hospitals and clinics more quickly. The...
  • Exclusive: Hospira talks with Danone on $5 billion tax inversion deal stall

    LONDON (Reuters) - U.S. drugmaker Hospira's HSP.N talks to buy the medical nutrition unit of Danone DANO.PA and use the deal to move its tax domicile abroad have stalled, according to people familiar with the matter, as attempts by U.S. companies to...
  • Novo Nordisk drops inflammation business to focus on diabetes

    COPENHAGEN (Reuters) - Danish pharmaceutical company Novo Nordisk has stopped research and development activities in inflammatory disorders to concentrate on the prevention and treatment of diabetes, its biggest business. This follows a decision to...
  • CytRx is pouring money into R&D of cancer-fighting drugs

    CytRx is pouring money into R&D of cancer-fighting drugs
    CytRx Corp. is on a mission to cure cancer — or at least slow it down. The Los Angeles biopharmaceutical company, which recently has become embroiled in a stock-promotion controversy, specializes in researching and developing drugs to treat...
  • 'Most exciting ever' Novartis drug points to huge sales

    BARCELONA (Reuters) - Sales forecasts for Novartis's new heart failure drug are being ramped up by analysts after strikingly good clinical trial results for a medicine doctors expect to transform treatment of the deadly disease. Shares in the Swiss...
  • Prostate cancer drug candidate shows great promise

    Prostate cancer drug candidate shows great promise
    A white powdered chemical compound emerged from two University of Maryland School of Medicine laboratories more than 10 years ago with a name destined for oblivion, but a future that now looks promising as a treatment for the most challenging cases of...
  • Exclusive: Akorn eyes $2 billion UCB unit in potential tax inversion - sources

    NEW YORK (Reuters) - U.S. specialty drugmaker Akorn Inc is exploring a bid for Belgian drugmaker UCB SA's U.S. subsidiary, a deal that would allow the company to move its tax domicile overseas in a practice known as inversion, according to people familiar...